Dermavant Sciences Annual Revenue, Number of Employees, Growth and Funding

Claim your profile


Phoenix, AZ USA
Total Funding:N/A
Lead Investor(s):NovaQuest Capital Management
Claim your profile

Industry Ranking

Growjo 10k Ranking

Estimated Revenue & Financials

  • Dermavant Sciences's estimated annual revenue is currently $8.8M per year.
  • Dermavant Sciences received $100.0M in venture funding in August 2018.
  • Dermavant Sciences's estimated revenue per employee is $155,000

Employee Data

  • Dermavant Sciences has 57 Employees.
  • Dermavant Sciences grew their employee count by 19% last year.
  • Dermavant Sciences currently has 2 job openings.

Executive Contacts

Kenneth PeistVP, Intellectual Property at Dermavant Sciences
Victoria ButnersAssociate Director Clinical Operations
Stephen AndrewsAssociate Director, Pharmaceutical Development, Analytical-cmc
Leisha MartinSenior Director Quality Assurance
Paul SeabackSVP, Technical Operations
Alan ColbornDirector, Pharmaceutical
Chad BerryhillExecutive Director of IT
Piyush JainDirector, CMC Product Development
Steve PiscitelliVice President, Clinical Pharmacology
Howie McKibbonSr. Vice President, Commercial Operations

A Passion for Science and a Commitment to Dermatology Dermavant Sciences is a specialty biopharmaceutical company developing innovative prescription therapies for dermatologic diseases. Dermavant has acquired promising compounds that address unmet therapeutic needs and has rapidly established a robust dermatology R&D pipeline. We are dedicated to realizing the full potential of biomedical research and to developing and commercializing novel first-in-class or best-in-class therapies that improve patients lives. The patient is at the heart of everything we do.



Number of Employees


Revenue (est)


Current Jobs


Employee Growth %


Total Funding







NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
Statistics & Da...
Sun Devil Athle...
Dermavant Scien...

Dermavant Sciences News

09/03/2019 - Dermavant Sciences officially withdraws $100 million IPO

Dermavant Sciences, a Phase 3 biotech developing in-licensed therapies for dermatological diseases, officially withdrew its plans for an initial ...

06/05/2019 - Dermavant Sciences Announces First Patient Dosed in ...

Dermavant Sciences Announces First Patient Dosed in PSOARING, its Pivotal Phase 3 Clinical Program for Tapinarof for the Topical Treatment ...

03/27/2019 - Dermavant Sciences Announces Appointment of Cyril ...

Dermavant Sciences Announces Appointment of Cyril Allouche as Chief Financial Officer and Provides Recent Corporate Update ...

Dermavant Sciences Funding

DateAmountRoundLead InvestorsReference
2018-08-29$100.0MUndisclosedNovaQuest Capital ManagementArticle

Dermavant Sciences Executive Hires

2017-10-02Vince IppolitoPresident/cooArticle
2018-04-04David RubensteinChief Scientific OfficerArticle
2018-09-05Frank TortiExecutive ChairArticle
2018-11-16Todd ZavodnickCEOArticle
2019-01-03Philip BrownChief Medical OfficerArticle
2019-03-28Cyril AlloucheChief Financial Officer (Chief Financial Officer)Article